Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: The OMERACT 9 v2 criteria

Walter P. Maksymowych, Robert Landewé, Paul Peter Tak, Christopher J. Ritchlin, Mikkel Østergaard, Philip J. Mease, Hani El-Gabalawy, Patrick Garnero, Dafna D. Gladman, Oliver FitzGerald, Daniel Aletaha, Vivien P. Bykerk, Joan M. Bathon, Silje W. Syversen, Maarten Boers, Piet Geusens, Robert D. Inman, Virginia B. Kraus, Tore K. Kvien, William J. TaylorGeorge A. Wells, Désirée Van Der Heijde

Research output: Contribution to journalArticle

Abstract

Objectives. A draft set of criteria for the validation of soluble biomarkers reflecting damage endpoints was proposed at OMERACT 8.At OMERACT 9 we aimed to scrutinize the necessity for each of these criteria according to the objectives of the working group. Methods. The OMERACT 8 draft criteria and the principle objectives of the validation process were clarified at a meeting of the working group in London, December 2007. A new framework was proposed after the following steps were conducted: (A) A systematic review of the literature focusing on the draft criteria and a preselected group of biomarkers (MMP3, CTX-II, RANKL, OPG, CTX-I) followed by a Delphi consensus exercise addressing the importance of individual criteria and identification of omissions in the draft set. (B) Formal debate as well as group discussion centered on the key arguments for inclusion/exclusion of specific criteria. (C) Onsite interactive electronic voting on the importance of specific criteria. The framework was presented and discussed at OMERACT 9 in both breakout and plenary sessions followed by a vote on its acceptance. Results. The objectives of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis biomarkers in relation to their predictive validity for damage endpoints was clarified and supported by OMERACT 9 participants. The OMERACT 8 draft validation criteria were reformulated into an essential category focused on criteria addressing the OMERACT Filter elements of discrimination (incorporating truth) and feasibility, and a desirable but nonessential category of other criteria addressing truth. This revised draft set was endorsed by participants at OMERACT 9. Conclusion. A revised set of validation criteria has been drafted by consensus at OMERACT 9 that focuses on the performance characteristics of biomarker assays, the importance of addressing potential confounders, and the essential requirement for clinical validation studies. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)1785-1791
Number of pages7
JournalJournal of Rheumatology
Volume36
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Psoriatic Arthritis
Rheumatoid Arthritis
Biomarkers
Consensus
Group Processes
Validation Studies
Ankylosing Spondylitis
Rheumatology
Politics

Keywords

  • Ankylosing spondylitis
  • Biomarkers
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Structural damage
  • Validation criteria

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis : The OMERACT 9 v2 criteria. / Maksymowych, Walter P.; Landewé, Robert; Tak, Paul Peter; Ritchlin, Christopher J.; Østergaard, Mikkel; Mease, Philip J.; El-Gabalawy, Hani; Garnero, Patrick; Gladman, Dafna D.; FitzGerald, Oliver; Aletaha, Daniel; Bykerk, Vivien P.; Bathon, Joan M.; Syversen, Silje W.; Boers, Maarten; Geusens, Piet; Inman, Robert D.; Kraus, Virginia B.; Kvien, Tore K.; Taylor, William J.; Wells, George A.; Van Der Heijde, Désirée.

In: Journal of Rheumatology, Vol. 36, No. 8, 08.2009, p. 1785-1791.

Research output: Contribution to journalArticle

Maksymowych, WP, Landewé, R, Tak, PP, Ritchlin, CJ, Østergaard, M, Mease, PJ, El-Gabalawy, H, Garnero, P, Gladman, DD, FitzGerald, O, Aletaha, D, Bykerk, VP, Bathon, JM, Syversen, SW, Boers, M, Geusens, P, Inman, RD, Kraus, VB, Kvien, TK, Taylor, WJ, Wells, GA & Van Der Heijde, D 2009, 'Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: The OMERACT 9 v2 criteria', Journal of Rheumatology, vol. 36, no. 8, pp. 1785-1791. https://doi.org/10.3899/jrheum.090346
Maksymowych, Walter P. ; Landewé, Robert ; Tak, Paul Peter ; Ritchlin, Christopher J. ; Østergaard, Mikkel ; Mease, Philip J. ; El-Gabalawy, Hani ; Garnero, Patrick ; Gladman, Dafna D. ; FitzGerald, Oliver ; Aletaha, Daniel ; Bykerk, Vivien P. ; Bathon, Joan M. ; Syversen, Silje W. ; Boers, Maarten ; Geusens, Piet ; Inman, Robert D. ; Kraus, Virginia B. ; Kvien, Tore K. ; Taylor, William J. ; Wells, George A. ; Van Der Heijde, Désirée. / Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis : The OMERACT 9 v2 criteria. In: Journal of Rheumatology. 2009 ; Vol. 36, No. 8. pp. 1785-1791.
@article{d22a3a92efbd477d99df3fecdce50b4f,
title = "Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: The OMERACT 9 v2 criteria",
abstract = "Objectives. A draft set of criteria for the validation of soluble biomarkers reflecting damage endpoints was proposed at OMERACT 8.At OMERACT 9 we aimed to scrutinize the necessity for each of these criteria according to the objectives of the working group. Methods. The OMERACT 8 draft criteria and the principle objectives of the validation process were clarified at a meeting of the working group in London, December 2007. A new framework was proposed after the following steps were conducted: (A) A systematic review of the literature focusing on the draft criteria and a preselected group of biomarkers (MMP3, CTX-II, RANKL, OPG, CTX-I) followed by a Delphi consensus exercise addressing the importance of individual criteria and identification of omissions in the draft set. (B) Formal debate as well as group discussion centered on the key arguments for inclusion/exclusion of specific criteria. (C) Onsite interactive electronic voting on the importance of specific criteria. The framework was presented and discussed at OMERACT 9 in both breakout and plenary sessions followed by a vote on its acceptance. Results. The objectives of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis biomarkers in relation to their predictive validity for damage endpoints was clarified and supported by OMERACT 9 participants. The OMERACT 8 draft validation criteria were reformulated into an essential category focused on criteria addressing the OMERACT Filter elements of discrimination (incorporating truth) and feasibility, and a desirable but nonessential category of other criteria addressing truth. This revised draft set was endorsed by participants at OMERACT 9. Conclusion. A revised set of validation criteria has been drafted by consensus at OMERACT 9 that focuses on the performance characteristics of biomarker assays, the importance of addressing potential confounders, and the essential requirement for clinical validation studies. The Journal of Rheumatology",
keywords = "Ankylosing spondylitis, Biomarkers, Psoriatic arthritis, Rheumatoid arthritis, Structural damage, Validation criteria",
author = "Maksymowych, {Walter P.} and Robert Landew{\'e} and Tak, {Paul Peter} and Ritchlin, {Christopher J.} and Mikkel {\O}stergaard and Mease, {Philip J.} and Hani El-Gabalawy and Patrick Garnero and Gladman, {Dafna D.} and Oliver FitzGerald and Daniel Aletaha and Bykerk, {Vivien P.} and Bathon, {Joan M.} and Syversen, {Silje W.} and Maarten Boers and Piet Geusens and Inman, {Robert D.} and Kraus, {Virginia B.} and Kvien, {Tore K.} and Taylor, {William J.} and Wells, {George A.} and {Van Der Heijde}, D{\'e}sir{\'e}e",
year = "2009",
month = "8",
doi = "10.3899/jrheum.090346",
language = "English (US)",
volume = "36",
pages = "1785--1791",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis

T2 - The OMERACT 9 v2 criteria

AU - Maksymowych, Walter P.

AU - Landewé, Robert

AU - Tak, Paul Peter

AU - Ritchlin, Christopher J.

AU - Østergaard, Mikkel

AU - Mease, Philip J.

AU - El-Gabalawy, Hani

AU - Garnero, Patrick

AU - Gladman, Dafna D.

AU - FitzGerald, Oliver

AU - Aletaha, Daniel

AU - Bykerk, Vivien P.

AU - Bathon, Joan M.

AU - Syversen, Silje W.

AU - Boers, Maarten

AU - Geusens, Piet

AU - Inman, Robert D.

AU - Kraus, Virginia B.

AU - Kvien, Tore K.

AU - Taylor, William J.

AU - Wells, George A.

AU - Van Der Heijde, Désirée

PY - 2009/8

Y1 - 2009/8

N2 - Objectives. A draft set of criteria for the validation of soluble biomarkers reflecting damage endpoints was proposed at OMERACT 8.At OMERACT 9 we aimed to scrutinize the necessity for each of these criteria according to the objectives of the working group. Methods. The OMERACT 8 draft criteria and the principle objectives of the validation process were clarified at a meeting of the working group in London, December 2007. A new framework was proposed after the following steps were conducted: (A) A systematic review of the literature focusing on the draft criteria and a preselected group of biomarkers (MMP3, CTX-II, RANKL, OPG, CTX-I) followed by a Delphi consensus exercise addressing the importance of individual criteria and identification of omissions in the draft set. (B) Formal debate as well as group discussion centered on the key arguments for inclusion/exclusion of specific criteria. (C) Onsite interactive electronic voting on the importance of specific criteria. The framework was presented and discussed at OMERACT 9 in both breakout and plenary sessions followed by a vote on its acceptance. Results. The objectives of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis biomarkers in relation to their predictive validity for damage endpoints was clarified and supported by OMERACT 9 participants. The OMERACT 8 draft validation criteria were reformulated into an essential category focused on criteria addressing the OMERACT Filter elements of discrimination (incorporating truth) and feasibility, and a desirable but nonessential category of other criteria addressing truth. This revised draft set was endorsed by participants at OMERACT 9. Conclusion. A revised set of validation criteria has been drafted by consensus at OMERACT 9 that focuses on the performance characteristics of biomarker assays, the importance of addressing potential confounders, and the essential requirement for clinical validation studies. The Journal of Rheumatology

AB - Objectives. A draft set of criteria for the validation of soluble biomarkers reflecting damage endpoints was proposed at OMERACT 8.At OMERACT 9 we aimed to scrutinize the necessity for each of these criteria according to the objectives of the working group. Methods. The OMERACT 8 draft criteria and the principle objectives of the validation process were clarified at a meeting of the working group in London, December 2007. A new framework was proposed after the following steps were conducted: (A) A systematic review of the literature focusing on the draft criteria and a preselected group of biomarkers (MMP3, CTX-II, RANKL, OPG, CTX-I) followed by a Delphi consensus exercise addressing the importance of individual criteria and identification of omissions in the draft set. (B) Formal debate as well as group discussion centered on the key arguments for inclusion/exclusion of specific criteria. (C) Onsite interactive electronic voting on the importance of specific criteria. The framework was presented and discussed at OMERACT 9 in both breakout and plenary sessions followed by a vote on its acceptance. Results. The objectives of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis biomarkers in relation to their predictive validity for damage endpoints was clarified and supported by OMERACT 9 participants. The OMERACT 8 draft validation criteria were reformulated into an essential category focused on criteria addressing the OMERACT Filter elements of discrimination (incorporating truth) and feasibility, and a desirable but nonessential category of other criteria addressing truth. This revised draft set was endorsed by participants at OMERACT 9. Conclusion. A revised set of validation criteria has been drafted by consensus at OMERACT 9 that focuses on the performance characteristics of biomarker assays, the importance of addressing potential confounders, and the essential requirement for clinical validation studies. The Journal of Rheumatology

KW - Ankylosing spondylitis

KW - Biomarkers

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

KW - Structural damage

KW - Validation criteria

UR - http://www.scopus.com/inward/record.url?scp=67149129603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149129603&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090346

DO - 10.3899/jrheum.090346

M3 - Article

C2 - 19671813

AN - SCOPUS:67149129603

VL - 36

SP - 1785

EP - 1791

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -